ARCHIVES

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

ASCO Report Urges 5% Annual Increase For NIH.

December 8, 2006

MSKCC Gets $100 Million Commitment From Mortimer Zuckerman For New Research Building.

May 12, 2006

Marker Research Plans Described; NCAB May Consider Asking For Special Study Section For Those Grants

March 11, 1983

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012

DC, DCR Boards Angered when NCI Ignored In AIDS Money Amendment

October 26, 1984

NC-Approved Clinical Trials

June 27, 2003